

# Paul Reichert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11375110/publications.pdf>

Version: 2024-02-01

13  
papers

960  
citations

933447

10  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

1137  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. <i>Nature Structural Biology</i> , 1999, 6, 233-242.                    | 9.7 | 397       |
| 2  | Zinc mediated dimer of human interferon- $\beta$ revealed by X-ray crystallography. <i>Structure</i> , 1996, 4, 1453-1463.   | 3.3 | 236       |
| 3  | Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 953-958.                             | 8.2 | 199       |
| 4  | A homology model of human interferon $\beta$ -2. <i>Proteins: Structure, Function and Bioinformatics</i> , 1993, 17, 62-74.  | 2.6 | 24        |
| 5  | Pembrolizumab microgravity crystallization experimentation. <i>Npj Microgravity</i> , 2019, 5, 28.   | 3.7 | 19        |
| 6  | Development of a novel class of potent and selective FIXa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4945-4949.                                   | 2.2 | 16        |
| 7  | Development of a novel tricyclic class of potent and selective FIXa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5437-5443.                         | 2.2 | 16        |
| 8  | Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 324-329. | 2.8 | 16        |
| 9  | Rapid development of two factor IXa inhibitors from hit to lead. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2321-2325.  | 2.2 | 14        |
| 10 | Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2622-2628.            | 2.2 | 10        |
| 11 | Type I interferon structures: Possible scaffolds for the interferon-alpha receptor complex. <i>Canadian Journal of Chemistry</i> , 2002, 80, 1166-1173.                          | 1.1 | 6         |
| 12 | Investigating Crystalline Protein Suspension Formulations of Pembrolizumab from MAS NMR Spectroscopy. <i>Molecular Pharmaceutics</i> , 2022, 19, 936-952.                        | 4.6 | 6         |
| 13 | Discovery of hydroxy pyrimidine Factor IXa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127279.   | 2.2 | 1         |